Drug Development and Approval Process

October 2006
Stations, the following is a news announcement. Suggested lead in 3, 2, 1...

(INTRO)

For the first time, the nation's leading pharmaceutical research companies have agreed to work together, with the federal government, on accelerating progress in disease-specific research. This unprecedented level of collaboration is designed to result in new, more effective medicines for diseases such as lymphoma and other cancers, diabetes, and depression.

Ellen Sigal, of Friends of Cancer Research and chair of the public-private partnership committee of the Foundation for the National Institutes of Health, which will oversee this effort, says this is good news for patients.

(SIGAL)

THIS COLLABORATION OFFERS HOPE TO THE MORE THAN 90 MILLION AMERICANS WITH CHRONIC DISEASE. THE RESEARCH CONDUCTED THROUGH THIS PARTNERSHIP WILL HELP IN THE DEVELOPMENT OF INNOVATIVE TREATMENTS AND LIFESAVING MEDICINES.

(CLOSE)

This public-private sector partnership is part of a larger initiative sponsored by the Food and Drug Administration, called Critical Path. The goal of Critical Path is to improve the nation's drug development and approval process. For more information, visit www.focr.org.